

Therapeutic outcomes of biologic switching in CRSwNP

A systematic review and meta-analysis

Systematic search conducted June 2025

Databases



WEB OF SCIENCE



Embase®



Cochrane Library

8


Articles

79.2%

R (59.6% - 100%)

Average success rate

470 patients



Switching reasons

Insufficient CRS symptom control

Undesirable side effects

Insufficient asthma symptom control

1 Clinical features

SNOT-22 decreased significantly from mean score of 49.6 to 14.2 with a 71.4% improvement rate

Nasal polyp score decreased significantly from 8.4 to 2.3

Asthma control score improved by an average of 33.2%

Olfactory function improved by an average of 71.5%



2 Lab features




IgE level declined from 179.5 to 25.6 IU/L

Eosinophil count increased from 0.33 to 0.54 × 10⁹ cells/L



3 Safety profile



► **Biologic switching found to be safe**

► **Side effects reported in only 1.3% of cases**